S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
ETR:EVT

Evotec Stock Forecast, Price & News

€35.63
+0.40 (+1.14%)
(As of 01/17/2022 12:00 AM ET)
Add
Compare
Today's Range
€34.94
€36.01
50-Day Range
€35.23
€44.58
52-Week Range
€27.80
€45.83
Volume
428,077 shs
Average Volume
1.36 million shs
Market Capitalization
$6.20 billion
P/E Ratio
23.82
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive EVT News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.


Evotec logo

About Evotec

Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.

Headlines

Evotec (ETR:EVT) PT Set at €50.00 by Royal Bank of Canada
January 18, 2022 |  americanbankingnews.com
DGAP-News: Evotec receives US$ 18 m grant for women's health
December 16, 2021 |  markets.businessinsider.com
Evotec AG: Evotec SE Announces Closing of Public Offering
November 11, 2021 |  finanznachrichten.de
DGAP-News: Evotec SE announces closing of public offering
November 9, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
3,735
Year Founded
N/A

Sales & Book Value

Annual Sales
$571.47 million
Cash Flow
€2.62 per share
Book Value
€6.02 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$6.20 billion
Optionable
Not Optionable

Company Calendar

Today
1/19/2022
Next Earnings (Estimated)
3/23/2022

MarketRank

Overall MarketRank

1.88 out of 5 stars

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Evotec (ETR:EVT) Frequently Asked Questions

Is Evotec a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Evotec stock.
View analyst ratings for Evotec
or view top-rated stocks.

How has Evotec's stock price been impacted by Coronavirus?

Evotec's stock was trading at €20.79 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EVT stock has increased by 71.4% and is now trading at €35.63.
View which stocks have been most impacted by COVID-19
.

When is Evotec's next earnings date?

Evotec is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Evotec
.

What price target have analysts set for EVT?

4 analysts have issued 12-month target prices for Evotec's shares. Their forecasts range from €33.00 to €55.00. On average, they anticipate Evotec's stock price to reach €46.17 in the next year. This suggests a possible upside of 29.6% from the stock's current price.
View analysts' price targets for Evotec
or view top-rated stocks among Wall Street analysts.

Who are Evotec's key executives?

Evotec's management team includes the following people:
  • Dr. Werner Lanthaler M.B.A., Ph.D., MBA, MPA, CEO & Member of Management Board (Age 53, Pay $1.06M)
  • Mr. Enno Spillner, CFO & Member of Management Board (Age 51, Pay $608k)
  • Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 57, Pay $792k)
  • Dr. Craig Johnstone, COO, Head of EVT Execute segment & Member of Management Board
  • Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting
  • Gabriele Hansen, Sr. VP Corp. Communications, Marketing & Investor Relations
  • Ms. Monika Conradt, Global Head of HR
  • Dr. Ian M. Hunneyball, Sr. VP of Programme Management & Clinical Operations (Age 71)
  • Dr. David Hallet, Exec. VP
  • Dr. Erich F. Greiner, Chief Innovation Officer (Age 55)

What other stocks do shareholders of Evotec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven Pharmaceutical (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC).

What is Evotec's stock symbol?

Evotec trades on the ETR under the ticker symbol "EVT."

What is Evotec's stock price today?

One share of EVT stock can currently be purchased for approximately €35.63.

How much money does Evotec make?

Evotec has a market capitalization of $6.20 billion and generates $571.47 million in revenue each year.

How many employees does Evotec have?

Evotec employs 3,735 workers across the globe.

What is Evotec's official website?

The official website for Evotec is www.evotec.com.

Where are Evotec's headquarters?

Evotec is headquartered at Essener Bogen 7, HAMBURG, 22419, Germany.

How can I contact Evotec?

Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.


This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.